Clinical Trials Browser

Stomach Neoplasms

Nasopharyngeal Carcinoma

Gestational Trophoblastic Disease

Endometrioid Endometrial Cancer

Carcinoma, Hepatocellular

Leukemia, Myeloid, Acute

Esophageal Neoplasms

Salivary Gland Neoplasms

Carcinoma, Hepatocellular

Liver Neoplasms

Locally Advanced Rectal Cancer

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Carcinoma, Hepatocellular, Liver Neoplasms

Uterine Cervical Neoplasms

Cholangiocarcinoma

Carcinoma, Hepatocellular

Pancreatic Neoplasms

Carcinoma, Hepatocellular

BRCA-Mutated Breast Carcinoma

Esophageal Squamous Cell Carcinoma

Gastric Cancer Adenocarcinoma Metastatic

Uterine Cervical Neoplasms

Uterine Cervical Neoplasms

Breast Neoplasms

Carcinoma, Hepatocellular, Liver Diseases

Liver Neoplasms

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Adrenocortical Carcinoma

Esophageal Neoplasms

Nasopharyngeal Carcinoma

Stomach Neoplasms

Unresectable Gallbladder Cancer

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

Colorectal Neoplasms

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Carcinoma, Hepatocellular

Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck

Nasopharyngeal Carcinoma

Pancreatic Neoplasms

Nasopharyngeal Carcinoma

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Triple Negative Breast Neoplasms

Breast Neoplasms

Clinical Trials

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

LEAF-02

TASK-05

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

CCGLC-001

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

NEOPCOSCC

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

BCTOP-T-N01

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

FOBECAMS

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer